Subscribe to:
POZ magazine E-newsletters
POZ Personals Sign In / Join
Username:
Password:

Back to home » Treatment News » Top Stories

Most Popular Stories
Life Expectancy With HIV Increases Dramatically
Strength Training Burns More Fat Than Endurance Exercise in HIV
New Anti-HIV Drug Target Discovered
A 'Functional Cure' for HIV?
Changing the HIV Treatment Paradigm
HIV Treatment Diminishes Non-AIDS Illnesses
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from CancerWEB's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Herpes Simplex Virus
Syphilis & Neurosyphilis
Shingles
The HIV Life Cycle
Human Papilloma Virus (HPV)
Treatments for Opportunistic Infections (OIs)
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to editors@aidsmeds.com.

Click here for more news


emailrssprint

July 11, 2008

Therapeutic Vaccine Tanks in Study

In another setback to HIV immunization research, the ALVAC 1452 therapeutic vaccine led to higher viral loads and less time off antiretroviral (ARV) treatment in HIV-positive patients in a study published in the July 11 issue of AIDS and reported by AIDSmap.

Therapeutic vaccines have a long history in AIDS research. Experts have been using various types of vaccines to stimulate the immune systems of people living with HIV—notably those with undetectable viral loads while on ARV treatment—in hopes that the new, more robust immune responses will help control viral replication in the absence of therapy. This theory was supported with the positive results of an earlier vaccine candidate, ALVAC 1433.

With the newer vaccine, Brigitte Autran, MD, from the Institut National de la Santé et de la Recherche Médicale (INSERM) in Paris, and her colleagues enrolled 66 people taking ARV treatment with CD4 counts over 350. Twenty-two people were given four doses of ALVAC 1452 over a 20-week period, 22 people received three doses, and 22 were given placebo.

Four weeks after the last dose of the vaccine or placebo, 56 of the 66 patients chose to stop ARV treatment. They agreed to restart treatment if their CD4 count dropped either below 250 or more than 50 percent from when they started the study, or if their viral load climbed above 50,000.

Autran’s team found that patients who received the vaccine ended up with much higher viral loads than patients who received a placebo, and that those who got four doses of the vaccine had higher viral loads even than those who got just three doses. Moreover, people who got four doses of the vaccine were four times as likely as the placebo group to have to restart ARV treatment.

As with the failure of the Merck preventive vaccine, it appears that the vaccine-induced immune stimulation actually harmed people more than it helped them, and Autran’s team state that they are keen to discover the reasons why this occurred.

Search: ALVAC 1452, ALVAC 1433, therapeutic vaccine, Brigitte Autran, INSERM


Scroll down to comment on this story.

emailrssprint

Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team review all comments before they are posted. Please do not include either ":" or "@" in your comment.)

| Posting Rules

Previous Comments:

comments 1 - 1 (of 1 total)    

ArgentineanGuy, Buenos Aires, 2008-07-15 19:40:41
god.. news like this makes me feel so bad. When all this s... is going to end?

comments 1 - 1 (of 1 total)    


[Go to top]

Get Started
Get Answers
I'm HIV positive. What's next?
How to find a support system
Things you should know before starting treatment
How to handle side effects and other concerns
How to tell someone you have HIV/AIDS

Conference Coverage

48th Annual ICAAC/IDSA 46th Annual Meeting
Washington, DC
October 25-28, 2008


XVII International AIDS Conference
Mexico City, Mexico
August 3-8, 2008


CROI 2008
Boston, MA
February 3-8, 2008


more conference coverage


[ about AIDSmeds | AIDSmeds advisory board | our staff | advertise/contact us]
© 2009 Smart + Strong. All Rights Reserved. Terms of use and Your privacy